Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Chubb
Merck
Baxter
Cerilliant
Chinese Patent Office
McKesson
Federal Trade Commission
Julphar
Boehringer Ingelheim

Generated: August 17, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Method and composition for administering an NMDA receptor antagonist to a subject
Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV)
Assignee: Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Filing Date:Nov 22, 2005
Application Number:11/285,905
Claims:1. A method of administering memantine to a human subject in need thereof, comprising 10-100 mg of: orally administering to the human subject once per day over multiple days a sustained release oral dosage form comprising memantine or a pharmaceutically acceptable salt thereof and a component that sustains release of the memantine or salt thereof, wherein a therapeutically effective daily dose of the memantine or salt thereof is administered from initiation of therapy without prior dose escalation of memantine, and wherein the subject has a condition selected from the group consisting of Alzheimer's disease, dementia, Parkinson's disease, and neuropathic pain.

2. The method of claim 1, wherein the sustained release component comprises a sustained release coating.

3. The method of claim 1, wherein the sustained release component comprises a sustained release matrix.

4. The method of claim 1, wherein the sustained release component comprises a sustained release coating and a sustained release matrix.

5. The method of claim 1, wherein the sustained release oral dosage form further comprises a delayed release component.

6. The method of claim 1, wherein the dosage form comprises a capsule or a tablet.

7. The method of claim 1, wherein the condition is dementia.

8. The method of claim 7, wherein the dementia is Alzheimer's disease dementia.

9. The method of claim 1, wherein the dosage form comprises 10-50 mg of memantine or salt thereof.

10. The method of claim 1, wherein the dosage form comprises at least 22.5 mg of memantine or salt thereof

11. In a method of avoiding side-effects in a human subject initiating memantine therapy, the improvement comprising orally administering to the subject once per day over multiple days a sustained release oral dosage form comprising 10-100 mg of memantine or a pharmaceutically acceptable salt thereof and a component that sustains release of the memantine or salt thereof, wherein a therapeutically effective daily dose of the memantine or salt thereof is administered from initiation of therapy without prior dose escalation of memantine, and wherein the subject has a condition selected from the group consisting of Alzheimer's disease, dementia, Parkinson's disease, and neuropathic pain.

12. The method of claim 11, wherein the sustained release component comprises a sustained release coating.

13. The method of claim 11, wherein the sustained release component comprises a sustained release matrix.

14. The method of claim 11, wherein the sustained release component comprises a sustained release coating and a sustained release matrix.

15. The method of claim 11, wherein the sustained release oral dosage form further comprises a delayed release component.

16. The method of claim 11, wherein the dosage form comprises a capsule or a tablet.

17. The method of claim 11, wherein the condition is dementia.

18. The method of claim 17, wherein the dementia is Alzheimer's disease dementia.

19. The method of claim 11, wherein the dosage form comprises 10-50 mg of memantine or salt thereof.

20. The method of claim 11, wherein the dosage form comprises at least 22.5 mg of memantine or salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Fish and Richardson
Chinese Patent Office
Johnson and Johnson
US Army
Teva
Baxter
Farmers Insurance
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot